SRP475477 PRJNA1047938 RNA seq of A549 cells after different dose cisplatin treatment P53 is the main target for cisplatin to exert antitumor effects, its mutation is one of the main factors for cisplatin resistance. Once cisplatin chemotherapy promotes TP53 mutation, resistance will further accumulate. Therefore, We performed RNA sequencing on A549 cells after different dose cisplatin treatment. To emphasize the necessity of fluvastatin addition, we performed RNA sequencing on fluvastatin treated A549 cells after moderate dose cisplatin induction.